Monoclonal Gammopathy of Undetermined Significance Clinical Trials in New York, New York
3 recruitingNew York, New York
Showing 1–3 of 3 trials
Recruiting
Phase 2
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
Smoldering Multiple Myeloma (SMM)Monoclonal Gammopathy of Undetermined Significance (MGUS)
Regeneron Pharmaceuticals116 enrolled39 locationsNCT06140524
Recruiting
Not Applicable
A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
Monoclonal Gammopathy of Undetermined SignificanceSmoldering Multiple Myeloma
Memorial Sloan Kettering Cancer Center180 enrolled8 locationsNCT05640843
Recruiting
Not Applicable
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
Multiple MyelomaMonoclonal Gammopathy of Undetermined SignificanceMultiple Myeloma, Smoldering
Memorial Sloan Kettering Cancer Center200 enrolled7 locationsNCT06055894